ClinicalTrials.gg
CompletedNCT07778472Updated Aug 21, 2026

Topical Tripelennamine 1% Cream Versus Diphenhydramine 1% Cream for the Relief of Histamine-Induced Itching: A Proof Concept Study in Healthy Adults.

An Early Phase 1 interventional study of Tripelennamine and Diphenhydramine in Healthy, sponsored by Palm Beach Atlantic University. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by Palm Beach Atlantic University · Early Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 1 month ago, and no results have been posted to the registry.
  • Registered 1 year 5 months after the study started (first participant enrolled Feb 2025, registered Aug 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 163 studies in Pruritus with a site in United States — 24 open to participants now, 28 under way, 8 of them phase 3. Pruritus · United States.

Enrollment
112th of 153
37 · median 70
Started
2025
with 10 others
Phase 1
10 of 163
3 open now
Registered
160th of 163
by date

Among the 163 studies in Pruritus with a site in United States, this one is the 112th largest by enrollment of the 153 interventional ones that give a count, is one of 11 that started in 2025, is one of 10 in phase 1, and was the 160th registered.

Pruritus

491 studies on the registry are indexed under Pruritus; 94 are open to participants now.

Browse Pruritus studies →

Open to participants now

24 of the 163 studies in Pruritus with a site in United States are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 54 Pruritus studies recruiting now, 22 (41%) set no upper age limit and 24 (44%) stop at 75 or younger; 15 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 163 studies in Pruritus with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to determine whether topical tripelennamine 1% cream can relieve histamine-induced itching and whether it is more effective than diphenhydramine 1% cream in healthy adults aged 18 to 50 years.

The main questions it aims to answer are:

  • Does tripelennamine 1% cream reduce the intensity, duration, and peak severity of histamine-induced itch as measured by a visual analog scale (VAS)?
  • Does tripelennamine 1% cream reduce the histamine-induced wheal and flare skin responses compared with diphenhydramine 1% cream and vehicle control? Researchers will compare tripelennamine 1% cream, diphenhydramine 1% cream, and a vehicle control cream base to see if tripelennamine provides greater relief of histamine-induced itching and skin reactions.

Participants will:

  • Have four test areas marked on their forearms.
  • Receive topical application of tripelennamine 1% cream, diphenhydramine 1% cream, and vehicle control cream to randomized test sites.
  • Undergo a histamine challenge administered through iontophoresis after treatment application.
  • Rate their itch intensity every minute using a 0 to 10 visual analog scale until the itch subsides.
  • Have wheal and flare skin reactions assessed every 5 minutes for up to 20 minutes, including photographs and videos of the reactions.
  • Report any adverse events for up to one week after study completion.
Read the detailed description

The goal of this clinical trial is to determine whether tripelennamine 1% topical cream is effective in relieving histamine-induced itching and skin reactions and whether it is more effective than diphenhydramine 1% topical cream in healthy adult volunteers aged 18 to 50 years with no history of chronic itch or conditions affecting itch perception. The study was conducted because there are limited over-the-counter topical medications that directly relieve acute itch, creating a need for more effective topical antipruritic treatments.

The main questions it aims to answer are:

  • Does tripelennamine 1% cream reduce the intensity of histamine-induced itch, as measured by a visual analog scale (VAS), including overall itch intensity (area under the itch-time curve), peak itch severity, and duration of itching?
  • Does tripelennamine 1% cream reduce histamine-induced skin reactions, specifically the magnitude and duration of flare and wheal responses, compared with diphenhydramine 1% cream and vehicle control? Researchers will compare tripelennamine 1% topical cream, diphenhydramine 1% topical cream, and a vehicle control cream base to determine whether tripelennamine provides superior relief of histamine-induced itch and associated skin reactions. The investigators hypothesized that participants treated with tripelennamine would experience significantly less itching and reduced flare and wheal responses following a histamine challenge than those treated with diphenhydramine or vehicle control.

Participants will:

  • Provide informed consent and undergo screening to confirm eligibility.
  • Have four 4 cm × 4 cm test areas marked on the inner surfaces of both forearms.
  • Receive randomized, double-blinded applications of:
  • Tripelennamine 1% topical cream,
  • Diphenhydramine 1% topical cream, and
  • Vehicle control cream base.
  • Have approximately 0.2 g of each study cream applied to designated skin sites and left in place for 15 minutes.
  • Undergo a histamine challenge at each treatment site using iontophoresis, a procedure that delivers histamine 1% gel through the skin using a low electrical current to induce itching and the characteristic histamine wheal-and-flare response.
  • Rate the intensity of itching every minute using a 0 to 10 visual analog scale, where 0 represents "no itch" and 10 represents the "worst itch imaginable," until the sensation completely resolves.
  • Have the duration and peak severity of itching recorded for each treatment condition.
  • Have skin flare and wheal reactions assessed and scored every 5 minutes for up to 20 minutes after the histamine challenge.
  • Have photographs and videos taken of the treatment sites to document flare and wheal responses over time.
  • Be monitored for adverse events during the study and report any adverse effects for up to one week after study completion.

This was a single-center, randomized, double-blind, vehicle-controlled clinical trial conducted at Palm Beach Atlantic University. Thirty-seven healthy adults were enrolled and thirty-six participants completed all efficacy assessments included in the final analysis.

03

Conditions studied

  • Healthy

Browse trials for

Keywords

  • Tripelennamine
  • Diphenhydramine
  • Histamine
  • Itch
  • VAS
  • Iontophoresis
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be in general good health with no disease or physical conditions that would impair evaluation of itch and pain perception.
  • No history of chronic itch or pain.
  • Must abstain from the use of any systemic or topical antihistamine, , or pain relief medications from the week prior to the study till the completion of the study.
  • Must abstain from the use of moisturizers on the arms 24 hours before study visit.

Exclusion criteria

Exclusion Criteria:

  • Inability to complete the required measures.
  • The presence of an itchy skin disease.
  • Diagnosis of disease that would affect itch or pain perception (e.g. neuropathies).
  • Currently enrolled in any study in which the subject is receiving any type of drug, biological, or non-drug therapy.
  • Use of oral, topical analgesics, or other medications known to interfere with itch or pain perception in the week prior to the study and throughout the study (e.g. antihistamines, anesthetics, opioids, neuroleptics, etc.).
  • Use of emollients on the arms a week prior to the study and throughout the study.
  • Known allergies to tripelennamine and/or diphenhydramine.
  • Pregnant women. (Women of will undergo an hCG pregnancy test).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
37 participants (actual)

Study arms

  • Placebo comparator
    Vehicle control cream base

    Participants received a single topical application of vehicle cream base prior to histamine iontophoresis to serve as a control condition.

    Drug: Vehicle Control Cream Base

  • Active comparator
    Diphenhydramine 1% topical cream

    Participants received a single topical application of diphenhydramine 1% cream prior to histamine iontophoresis to evaluate its effect on histamine-induced itch and skin reactions.

    Drug: Diphenhydramine

  • Experimental
    Tripelennamine 1% topical cream

    Participants received a single topical application of tripelennamine 1% cream prior to histamine iontophoresis to evaluate its effect on histamine-induced itch and skin reactions.

    Drug: Tripelennamine

Interventions

  • DrugTripelennamine

    Tripelennamine 1% topical cream applied to the skin of one arm of an individual 15 minutes before the application of iontophoretically administered histamine 2% gel.

    Also known as: Pyribenzamine

  • Diphenhydramine 1% topical cream applied to the skin of one arm of an individual 15 minutes before the application of iontophoretically administered histamine 2% gel.

  • DrugVehicle Control Cream Base

    Approximately 0.2 g of vehicle cream base without antihistamine was applied topically to designated forearm test areas. The cream remained on the skin for 15 minutes before histamine iontophoresis was performed.

06

What researchers measure

Primary outcomes

  1. VAS

    The effectiveness of tripelennamine 1% cream compared to diphenhydramine 1% cream in relieving histamine-induced itching was determined using a visual analogue scale for pruritus (VAS) as an endpoint. The following parameters were determined from the VAS itch score vs time curves: area under the curve, peak VAS itch score and duration of itch.

    Time frame: Subjects rated their itch intensity every 60 seconds until the itch sensation had completely subsided using a visual analog scale (VAS) for 60 minutes.

Secondary outcomes

  1. Histamine Triple Response

    The effectiveness of tripelennamine 1% cream compared to diphenhydramine 1% cream in relieving the histamine-induced triple response was determined via the following endpoints: * The magnitude of a wheal as a function of time. * The magnitude of a flare as a function of time.

    Time frame: Research assistants rated the magnitude of the wheal and flare in 5-minute intervals for up to 20 minutes using a rating of 1-mild, 2-moderate, 3-severe.

07

Study locations

1 site
  • Palm Beach Atlantic University
    West Palm Beach, Florida 33401, United States
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified participant-level data supporting the published results, including demographics, VAS itch scores, itch duration, peak itch scores, wheal and flare assessments, treatment assignment, and adverse event data.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: Beginning 6 months following publication of primary results and ending 5 years after publication.

Access criteria: Available to qualified researchers upon reasonable request, review and approval of a research proposal, and execution of a Data Use Agreement.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2025 to primary completion in Sep 2025, 6 months.

Of 21 phase 1 interventional studies under Pruritus, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's 6 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2026
First posted
Aug 21, 2026
StartActual
Feb 24, 2025
Primary completionActual
Sep 18, 2025
CompletionActual
Sep 18, 2025
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07778472
Lead sponsor
Palm Beach Atlantic University
Responsible party
Adwoa Olufunlayo Nornoo (Principal Investigator, Palm Beach Atlantic University) — Principal investigator
First posted
Aug 21, 2026
Start date
Feb 24, 2025
Primary completion
Sep 18, 2025
Completion
Sep 18, 2025
Last update
Aug 21, 2026

Study contacts

David M Compton, PhD
study chair · Palm Beach Atlantic University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion